2020
DOI: 10.1101/2020.09.12.294355
|View full text |Cite
Preprint
|
Sign up to set email alerts
|

Idiosyncratic variation in the fitness costs of tetracycline-resistance mutations inEscherichia coli

Abstract: A bacterium's fitness relative to its competitors, both in the presence and absence of antibiotics, plays a key role in its ecological success and clinical impact. In this study, we examine whether tetracycline-resistant mutants are less fit in the absence of the drug than their sensitive parents, and whether the fitness cost of resistance is constant or variable across independently derived lines. Tetracycline-resistant lines suffered, on average, a reduction in fitness of almost 8%. There was substantial amo… Show more

Help me understand this report
View published versions

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2020
2020
2021
2021

Publication Types

Select...
1
1

Relationship

1
1

Authors

Journals

citations
Cited by 2 publications
(1 citation statement)
references
References 60 publications
(63 reference statements)
0
1
0
Order By: Relevance
“…This variation suggests that bacteria and cancers have access to multiple resistance mutations with different collateral sensitivity profiles, such that replicates can accumulate different mutations simply due to the intrinsic randomness of the evolutionary process (Jerison et al, 2020). However, the variability of collateral effects among resistance mutations has not been characterized (but see Card et al, 2021), and there is no principled approach for accounting for this variability in designing robust multi-drug treatments. In particular, it is unclear which evolutionary parameters determine the expected collateral outcomes of evolution and, importantly, the uncertainty around these expectations.…”
Section: Introductionmentioning
confidence: 99%
“…This variation suggests that bacteria and cancers have access to multiple resistance mutations with different collateral sensitivity profiles, such that replicates can accumulate different mutations simply due to the intrinsic randomness of the evolutionary process (Jerison et al, 2020). However, the variability of collateral effects among resistance mutations has not been characterized (but see Card et al, 2021), and there is no principled approach for accounting for this variability in designing robust multi-drug treatments. In particular, it is unclear which evolutionary parameters determine the expected collateral outcomes of evolution and, importantly, the uncertainty around these expectations.…”
Section: Introductionmentioning
confidence: 99%